Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-25 @ 4:07 AM
Ignite Modification Date:
2025-12-25 @ 4:07 AM
NCT ID:
NCT07196020
Eligibility Criteria:
Inclusion Criteria:
* Patients with a diagnosis of ovarian, lung, gastric or pancreatic cancer scheduled to undergo a course of chemotherapy who are undergoing adjuvant or neoadjuvant chemotherapy, or who are undergoing chemotherapy for relapsed disease or patients receiving targeted therapy in combination with chemotherapy
* Patients who are over 18 years of age
* Patients who are able to give full and informed written consent
Exclusion Criteria:
* Prior history of a documented VTE event within the last 5 years (excluding central line associated events whereby patients completed anticoagulation \> 3 months previously)
* Any history of significant haemorrhage (requiring hospitalization or transfusion) outside of a surgical setting within the last 5 years
* Familial bleeding diathesis
* Known diagnosis of disseminated intravascular coagulation.
* Surgery within 2 weeks of first baseline sample (with the exception of porth-a-cath implantation or biopsy)
* Chemotherapy or immunotherapy 4 weeks before first baseline sample
* Currently receiving long term anticoagulant therapy (Low Molecular Weight Heparin(LMWH), Direct Oral Anticoagulants(DOACs), Warfarin). Patients receiving aspirin, ticlopidine, clopidogrel or LMWH at a prophylactic dosage for a short period (ie post cancer surgery or during short hospital stay) will be included provided they have completed thromboprophylaxis therapy at the first blood sampling time point.
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
18 Years
Study:
NCT07196020
Study Brief:
Protocol Section:
NCT07196020